Articles by Tom von Gunden
-
Patient Safety Through Overdose Protection With Elysium Therapeutics' Greg Sturmer
11/18/2024
Drug overdoses can result both from knowingly risky behavior, such as opioid use disorder, and from unwitting patient acts of over-consumption. In this episode of Sit and Deliver, Greg Sturmer, co-founder and CEO of biopharmaceutical company Elysium Therapeutics, talks with Sit and Deliver host Tom von Gunden about ways to add overdose inhibitors to oral medications prone to abuse or misuse.
-
Needle-Free Rescue Therapies With Crossject's Patrick Alexandre And Dan Chiche
11/12/2024
Just how quickly might the emergency treatment of an epileptic seizure or other sudden, chronic attack be enabled? With advances in needle-free autoinjectors, the promise of near immediacy is near. In this episode of In Combination, host Tom von Gunden combines perspectives from two different executive roles at emergency medicines company Crossject. CEO Patrick Alexandre and Chief Medical Officer Dan Chiche discuss common rescue scenarios, rapid self-administration of treatments, and collaborative development efforts across drug formulation and device engineering.
-
Intranasal Delivery for Post-Viral Smell Loss with Cyrano Therapeutics' Rick Geoffrion
10/29/2024
COVID-19 and other viruses have drawn increased attention to the debilitating effects and potentially consequential underlying causes of hyposmia or anosmia (reduced or complete inability to smell). In this episode of Sit and Deliver, Rick Geoffrion, founder and CEO of regenerative medicine company Cyrano Therapeutics, talks with Sit and Deliver host Tom von Gunden about why an effective therapeutic response may well involve – you guessed it – a payload through the nose.
-
Partnering On Patient Needs With DSM-Firmenich's George Mihov And Lukasz Koroniak
10/23/2024
Principal Scientist George Mihov and Global Biomaterials Director Lukasz Koroniak from DSM-Firmenich join Supplier Horizons host Tom von Gunden to discuss partnering with pharma on formulation development. Among the topics covered are translational research, materials development, and complex molecules required for biologic-based therapies.
-
Defining and Regulating Combination Products: An Evolutionary Journey
10/15/2024
In this episode of The Combination Products Handbook: The Series, host Tom von Gunden discusses Chapter 1 of The Combination Products Handbook: A Practical Guide for Combination Products and Other Combined Use Systems (CRC Press, 2023) with the book’s editor, Susan Neadle. Given that the initial chapter was penned by the FDA’s John “Barr” Weiner, the discussion focuses on reasons for establishing the historical and regulatory context for combination products early in the handbook’s topic coverage.
-
What Is There to Learn from a Combination Products Handbook? Plenty!
10/15/2024
In this initial episode of The Combination Products Handbook: The Series, a chapter-by chapter videocast series introducing topics from The Combination Products Handbook: A Practical Guide for Combination Products and Other Combined Use Systems (CRC Press, 2023), host Tom von Gunden discusses the book’s intent with its editor, Susan Neadle. The discussion focuses on the rationale for each chapter and the expert contributions of various chapter authors and co-authors.
-
Combination Products Regulatory Considerations with FDA's Barr Weiner
10/1/2024
From his roles and experiences in the combination products and combined use systems arena, John “Barr” Weiner offers perspectives on how to approach pre- and post-market activities with regulatory requirements and guidance in mind. Cross-functional coordination, integrated development, and primary mode of action (PMOA) designations are among the considerations Barr reminds organizations to implement thoughtfully as they work to advance combination products within a regulatory landscape.
-
Drug Device Availability, Sustainability, and Integrity with Windgap Medical's Aaron Mann
9/25/2024
CEO Aaron Mann of multi-platform drug delivery company Windgap Medical joins Supplier Horizons host Tom von Gunden to discuss drivers of innovation in injectable delivery. Expanding patient access to new and emerging therapies, reducing costs, and bolstering sustainability are among the topics covered in a conversation focused on benefits to patients.
-
LNP-Delivered mRNA via Inhalation with Ethris' Carsten Rudolph and Thomas Langenickel
9/18/2024
How can genetic information be carried into lung tissue for the treatment of asthma and potentially other conditions? In this inaugural episode of In Combination, host Tom von Gunden combines the perspectives of two executives from LNP/mRNA (lipidoid nanoparticle / messenger RNA) formulation and delivery platform developer Ethris: CEO Carsten Rudolph and Chief Medical Officer Thomas Langenickel. The conversation illuminates the value to patients of platform approaches to inhalation-delivered treatments.
-
Oral Small Molecule Targeting of Cancer with Cantex' Stephen Marcus
9/17/2024
Dr. Stephen Marcus boasts drug development experience across various routes of administration targeting varied therapeutic areas. Now as Cantex CEO, he leans on his background as an oncologist to drive his passion for effectively treating cancer while easing the patient experience. In this episode of Sit and Deliver, host Tom von Gunden asks Dr. Marcus about innovations in small molecule delivery for complex, life-threatening conditions.